tradingkey.logo

GSK plc

GSK
View Detailed Chart
47.025USD
+1.095+2.38%
Market hours ETQuotes delayed by 15 min
97.46BMarket Cap
22.03P/E TTM

GSK plc

47.025
+1.095+2.38%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.38%

5 Days

+6.25%

1 Month

+14.42%

6 Months

+20.67%

Year to Date

+39.04%

1 Year

+23.20%

View Detailed Chart

TradingKey Stock Score of GSK plc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GSK plc's Score

Industry at a Glance

Industry Ranking
51 / 160
Overall Ranking
138 / 4623
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Hold
Current Rating
43.255
Target Price
-1.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

GSK plc Highlights

StrengthsRisks
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Overvalued
The company’s latest PE is 21.02, at a high 3-year percentile range.
Fairly Valued
The company’s latest PE is 12.96, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 387.77M shares, decreasing 2.15% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 659.87K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.

Financial Indicators

EPS

No Data

Total revenue

No Data

GSK plc Info

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Ticker SymbolGSK
CompanyGSK plc
CEOMs. Deborah Waterhouse
Websitehttps://www.gsk.com/
KeyAI